Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1994-12-29
1997-09-02
Loring, Susan A.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
4241421, 4241301, 4241411, 4241821, 4241781, 5303884, 53038815, 5303871, 5303917, A61K 3940, A61K 39395, C07K 1600, C07K 1612
Patent
active
056629052
ABSTRACT:
Cell lines have been produced that secrete human monoclonal antibodies capable of binding to the lipopolysaccharide molecules of selected Pseudomonas aeruginosa IATS serotypes. Pharmaceutical compositions containing these antibodies, which can be in combination with other monoclonal antibodies, blood plasma fractions and antimicrobial agents, and the prophylactic and therapeutic use of such compositions in the management of infections are included. Prior to filing of this patent application the continuous transformed human cell lines 1C1, 6D6 and 8H7 described herein were deposited in the American Type Culture Collection and given the designations CRL 8941, 9171, and 9258, respectively.
REFERENCES:
patent: 4464465 (1984-08-01), Lostrom
patent: 4587121 (1986-05-01), Collins et al.
patent: 4677070 (1987-06-01), Larrick et al.
patent: 4683196 (1987-07-01), McLaughlin
patent: 4702910 (1987-10-01), Fukuda et al.
patent: 4734279 (1988-03-01), Stephan et al.
patent: 4772464 (1988-09-01), Rutherford et al.
patent: 4777136 (1988-10-01), Young
patent: 4834975 (1989-05-01), Siadak et al.
patent: 4970070 (1990-11-01), Raff
Coriani, R. L. et al., Proceedings of the Int. Workshop of Monoclonal Antibodies and Breast Cancer, pp. 248-268, Nov. 8-9, 1984.
Galloway, D. R. et al., Inf. & Immun., 44(2):262-267, May 1984.
Stone, R., Science, 259:1243, 26 Feb. 1993.
Fitzer-Schiller, G., The Washington Post, D3, Jan. 19, 1993.
Spaulding, B.J., Bio/Technology, 11:428-429, Apr. 1993.
Waldmann, T.A., Science, 252: 1657-1662, Jun. 1991.
Osband, M.E. et al., Immunology Today, 11(16): 193-195, 1990.
Zinner, et al., "Effects of IgM and IgG Antibody in Patients with Bacteremia Due to Gram-Negative Bacilli," J. Infect. Dis. 133:37-45 (1976).
Pollack, "Antibody-Mediated Immunity in Pseudomonas Disease and Its Clinical Application," Immunoglobulins: Characteristics and Uses of Intravenous Preparations, Alving and Finlayson, eds. pp. 73-79, U.S. Department of Health and Human Services, (1979).
Pollack, et al., "Protective Activity of Antibodies to Exotoxin A and Lipopolysaccharide at the Onset of Pseudomonas aeruginosa Septicemia in Man," J. Clin. Invest. 63:276-279 (1979).
Clumeck et al., "Humoral Immunity and Circulating Immune Complexes in Gram-Negative Bacteremia and Septic Shock," Bacterial Endotoxins & Host Response, Agarwal (ed.) Elsevier/North-Holland Biomedical Press, pp. 79-93, (1980).
Koskimies, "Human Lymphoblastoid Cell Line Producing Specific Antibody against Rh-Antigen D," Scand. J. Immunol. 11:73-77 (1980).
Hancock, et al., "Monoclonal Antibodies Against Pseudomonas aeruginosa Outer Membrane Antigens: Isolation and Characterization," Infect. Immun. 37:166-171 (1982).
Sadoff, et al., Program & abstracts of the Twenty-Second Interscience Conference on Antimicrobiol Agents & Chemotherapy, Abstract No. 253, (1982).
Pier et al., "Safety and Immunogenicity of High Molecular Weight Polysaccharide Vaccine from Immunotype 1 Pseudomonas aeruginosa," J. Clin. Invest. 69:303-308 (1982).
Mackie et al., "Immune Response of the Mouse to Gram-Negative Bacterial Outer Membrane Extracts as Assessed with Monoclonal Antibodies," J. Immunol. 129:829-832 (1982).
Liu, et al., "Survey of Heat-Stable, Major Somatic Antigens of Pseudomonas aeruginosa," Int. J. Systematic Bacteriology 33:256-264 (1983).
Yarchoan et al., "Limiting Dilution Analysis of Esptein-Barr Virus-Induced Immunoglobulin Production by Human B Cells," J. Exper. Med. 157:1-14 (1983).
Cryz et al., "Protection Against Pseudomonas aeruginosa Infection in a Murine Burn Wound Sepsis Model by Passive Transfer of Antitoxin A, Antielastase and Antilipopolysaccharide," Infect. Immun. 39:1072-1079 (1983).
Lam et al., "Immunogenicity of Pseudomonas aeruginosa Outer Membrane Antigens Examined by Crossed Immunoelectrophoresis," Infect Immun. 42:88-98 (1983).
Darveau, et al., "Procedure for Isolation of Bacterial Lipopolysaccharides from Both Smooth and Rough Pseudomonas aeruginosa and Salmonella typhimurium strains," J. Bacteriol. 155:831-838 (1983).
Collins, et al., "Protective Activity of an Intravenous Immune Globulin (Human) Enriched in Antibody against Lipopolysaccharide Antigens of Pseudomonas aeruginosa," Am. J. Med. pp. 168-174 (1984).
Pier et al., "Immunochemical Characterization of High-Molecular-Weight Polysaccharide From Fisher Immunotype 3 Pseudomonas aeruginosa, " Infect. Immun. 45:309-313 (1984).
Sawada et al., "Protection Against Infection with Pseudomonas aeruginosa Passive Transfer of Monoclonal Antibodies to Lipopolysaccharides and Outer Membrane Proteins," J. Infect. Dis. 150:570-576 (1984).
Steinitz et al., "Human Anti-Pneumococci Antibody Produced by an Epstein Barr Virus (EBV)-Immortalized Cell Line," J. Immunol. 132:877-882 (1984).
Teng et al., "Protection against Gram-Negative Bacteremia and Endotoxemia with Monoclonal IgM Antibodies," Proc. Natl. Acad. Sci. USA 82:1790-1794 (1985).
Sadoff et al., "Characterization of Mouse Monoclonal Antibodies Directed against Pseudomonas aeruginsoa Lipopolysaccharides," Antibiot. Chemother. 36:134-146 (1985).
Sawada et al. "Characterization of a Human Monoclonal Antibody to Lipopolysaccharides of Pseudomonas aeruginosa Serotype 5: A Possible Candidate as an Immunotherapeutic Agent for Infections with P. aeruginosa," J. Infect Dis. 152:965-970 (1985).
Siadak and Lostrom, "Cell-Driven Viral Transformation," Human Hybridomas & Monoclonal Antibodies, Engleman et al., eds. Plenum Publishing Corp., p. 167-185 (1985).
Hornberger et al., "Human Monoclonal Antibodies Against Gram-Negative Bacteria," Fed. Am. Soc. Exp. Biol., 69th Annual Meeting, Abstracts of Papers, No. 5366 (1985).
Larrick et al., "Generation and Characterization of Human Monoclonal Anti-Pseudomonas aeruginosa Antibodies," Human Hybridomas: Diagnostic and Therapeutic Applications in A.J. Strelkaukas (ed.) pp. 65-80 (1987).
Larrick, U.S. Statutory Invention Reg. No. H494, Jul. 5, 1988.
Zweerink et al., "Human Monoclonal Antibodies that Protect Mice against Challenge with Pseudomonas aeruginosa," Infect. Immun. 56:1873-1879 (1988).
Lang et al., "Isolation and Characterization of a Human Monoclonal Antibody that Recognizes Epitopes Shared by Pseudomonas aeruginosa Immunotype 1, 3, 4 and 6 Lipopolysaccharides," Infect. Immun. 57:1873-1879 (1989).
Hector et al., "Treatment of Experimental Pseudomonas aeruginosa Pneumonia with a Human IgM Monoclonal Antibody," J. Infect. Dis. 160:483-489 (1989).
Lang et al., "Immunoprotective Capacities of Human and Murine Monoclonal Antibodies Recognizing Serotype-Specific and Common Determinants of Gram-negative Bacteria," Therapeutic Monoclonal Antibodies, Borrebaeck and Larrick, eds., pp. 223-234 (1990).
Verhoef, et al., "Prospects for Monoclonal Antibodies in the Diagnosis and Treatment of Bacterial Infections," J. Clin. Microbiol. Infect. Dis. 9:247-250 (Apr., 1990).
Cross, et al., "Choice of Bacteria in Animal Models of Sepsis," Infect. Immun., 61(7):2741-2747 (Jul., 1993).
Rosok Mae J.
Siadak Anthony W.
Bristol--Myers Squibb Company
Loring Susan A.
LandOfFree
Monoclonal antibody compositions cross-reactive and cross-protec does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibody compositions cross-reactive and cross-protec, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibody compositions cross-reactive and cross-protec will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-306079